Specific treatment for hemolytic uremic syndrome will be established by your physician based on your individual condition. There is no known treatment that can stop the progress of the syndrome once it has started. Most treatments are aimed at easing the immediate symptoms and signs of this disease and at preventing further complications.
Typical hemolytic uremic syndrome is a self-limiting disease with spontaneous recovery. Treatment of HUS is supportive, with particular attention to management of intravenous fluids for rehydration and rebalancing of electrolytes like sodium and potassium, which can be lost with the diarrhea.
Hemolytic uremic syndrome treatment may include:
Strict fluid balance monitoring is important in detecting early renal failure. If failure develops, it should be handled aggressively by starting renal replacement therapy (such peritoneal dialysis, hemodialysis).
Blood transfusion are only used for the most severe cases of anemia in which the hemoglobin falls below 6 or 7 g/dL (depending on age, the normal value is 11-16). Blood transfusion given through an intravenous (IV) needle, may help reverse these signs and symptoms.
Plasma exchange (plasmapheresis combined with fresh-frozen plasma replacement) is currently the helpful treatment for HUS. Plasma exchange is removing the plasma and replacing it with donor plasma. It is performed daily until the platelet count normalizes. Plasma exchange is generally reserved for the most severe cases.
Kidney dialysis. Sometimes dialysis is needed to filter waste and excess fluid from the blood. Dialysis is usually a temporary treatment until the kidneys begin functioning adequately again. If the kidney damage is significant, however, permanent kidney failure, requiring long-term dialysis or a kidney transplant.
Good nutrition, you may require intravenous (IV) nutrition if you have severe digestive tract complications.
Antibiotics agents are not recommended as treatments for hemolytic uremic syndrome during the diarrheal stage of the disease. Antibiotic usage in children with E. coli O157:H7 infections show an increased risk of complications from hemolytic uremic syndrome.